Loading...
Please wait, while we are loading the content...
Similar Documents
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
| Content Provider | SAGE Publishing |
|---|---|
| Author | Gounant, Valérie Brosseau, Solenn Zalcman, Gérard |
| Copyright Year | 2021 |
| Abstract | Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1, LATS2WT1, p16, as well as BAP-1tumor-suppressor genes, which usually regulate apoptosis, cell invasion, motility, cell division, chromatin remodeling, as well as control of DNA repair. In few selected patients, debulking surgery consisting of pleurectomy-decortication is carried out, resulting in unsatisfactory long-term results. For about 15 years, first-line chemotherapy has been primarily based on a doublet of pemetrexed and cisplatin. Adding the monoclonal antibody bevacizumab (Avastin®), which targets vascular endothelial growth factor (VEGF), has been shown to improve overall survival (OS) by nearly 19 months. The emergence of immune check-point inhibitors (ICIs) in MPM treatment has recently been associated with substantial survival improvements in both second- and first-line settings. Similarly to non-small-cell lung cancer (NSCLC) patients, on-going trials are presently exploring the chemotherapy-ICI combination in MPM management, and depending on their results, this combination could represent a further major advance in this previously orphan disease. The current article reviews recent clinical trial results, as well as future clinical developments in this moving field. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/17588359211061956?download=true |
| ISSN | 17588359 |
| Volume Number | 13 |
| Journal | Therapeutic Advances in Medical Oncology (TAM) |
| e-ISSN | 17588359 |
| DOI | 10.1177/17588359211061956 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2021-12-10 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © The Author(s), 2021 |
| Subject Keyword | immunotherapy malignant pleural mesothelioma PD-1 CTLA-4 PD-L1 checkpoints inhibitors |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
